
Lower-Dose CagriSema: About 21% Weight Loss in REDEFINE 9
Lower doses of CagriSema still produced big weight loss. In REDEFINE 9, a phase 3 trial presented at ObesityWeek on November 14, 2026 and published the same day in The Lancet Diabetes & Endocrinology, adults on the two lower doses lost about 21% of their body weight on average at 68 weeks, versus 2.0% on placebo. The two lower doses landed in almost the same place. The honest fine print: it was a small trial (309 people), those headline numbers use a best-case way of counting, and CagriSema is still not FDA-approved, with a decision expected in Q4 2026.
Key facts
- Trial: REDEFINE 9, phase 3, 68 weeks, 309 adults with obesity or overweight and no diabetes, funded by Novo Nordisk (Nov 14, 2026).
- Result: 20.7% average weight loss on CagriSema 1.7 mg / 1.7 mg and 21.0% on 1.0 mg / 1.0 mg vs 2.0% on placebo (efficacy estimand).
- Counting everyone who started: 19.4% and 18.6% vs 4.6% on placebo (treatment regimen estimand).
- Hit 20% or more: about half of people on either dose (51.3% and 48.3%) vs 2.7% on placebo.
- Stopped for side effects: 2.9% and 4.9% vs 4.9% on placebo.
- Status, as of Nov 17, 2026: investigational. Novo filed the higher 2.4 mg / 2.4 mg dose with the FDA in December 2025; a decision is expected in Q4 2026.
What is CagriSema, quickly?
CagriSema is Novo Nordisk’s once-weekly injection that pairs two peptides: semaglutide, the GLP-1 medicine in Wegovy, and cagrilintide, a long-acting version of amylin, a fullness hormone released alongside insulin. Our CagriSema 2026 overview covers the big trials and the FDA filing. This post is only about the new lower-dose trial.
What did REDEFINE 9 test?
Most CagriSema trials used 2.4 mg / 2.4 mg, the dose Novo filed with the FDA. REDEFINE 9 is the first phase 3 trial to test it below that, per Novo. People were randomized to one of two lower doses or a matching placebo, and everyone also got lifestyle support. Per Healio, participants averaged 48 years old, 77% were women, and average BMI was 39.1. Average starting weight was 109.5 kg (about 241 lb).
The results at week 68:
| Group | Weight change (efficacy estimand) | Weight change (everyone who started) | Lost 10% or more | Lost 20% or more | Waist change |
|---|---|---|---|---|---|
| CagriSema 1.7 / 1.7 mg | -20.7% | -19.4% | 87.3% | 51.3% | -17.2 cm |
| CagriSema 1.0 / 1.0 mg | -21.0% | -18.6% | 86.0% | 48.3% | -17.5 cm |
| Placebo (pooled) | -2.0% | -4.6% | 13.6% | 2.7% | -3.6 cm |
The 10% and 20% columns use the efficacy estimand. At least 95% of people on either dose lost 5% or more of their body weight, versus 33.4% on placebo. All comparisons with placebo were statistically significant.
Why lower doses are good news
For a lot of people, the limiting factor with these drugs is not the result, it is the stomach. A dose that works with fewer side effects, or a step down for someone who reaches their goal, would give providers more room to fit treatment to the person. REDEFINE 9 suggests CagriSema still delivers 20%-range weight loss below the filed dose. Lead author Sean Wharton of the University of Toronto said the findings “have potential to inform clinical practice.”
There is also a puzzle here. The 1.0 mg dose did as well as the 1.7 mg dose. Presenter Deborah Horn of the University of Texas told Healio that adherence does not explain it, since people were taking the dose they were assigned: “More for you and I to learn.” Average weekly doses actually received were 1.3 mg and 0.8 mg in the two groups.
The fine print, told plainly
- Small trial. 309 people is small next to REDEFINE 1, which had 3,417. The trial was not built to tell the two doses apart, so “1.0 mg works as well as 1.7 mg” is an observation, not a proven finding.
- Best-case counting. The 20.7% and 21.0% assume everyone stayed on treatment. Counting everyone who started, it was 19.4% and 18.6%, and the gap over placebo shrinks to about 14 to 15 points.
- Side effects are still common. Any adverse event: 99% and 95% on CagriSema vs 91% on placebo, mostly stomach-related and mild to moderate. Novo did not publish separate nausea or vomiting rates for this trial. In the larger REDEFINE 1 trial at the full dose, stomach side effects hit 79.6% on CagriSema vs 39.9% on placebo.
- No deaths occurred during the study, per Healio.
- Industry-funded. Novo paid for the trial, and the presenter reports consulting for several drugmakers, including Novo and Lilly.
Also from Novo at ObesityWeek
A separate after-the-fact (post hoc) look at REDEFINE 1 found 67.8% of people on full-dose CagriSema lost at least 5% of their weight by week 8. Those early responders were down 25.4% at week 68, versus 17.8% for people who started slower. Novo itself says this is hypothesis-generating and not a basis for changing treatment decisions.
When could CagriSema be available?
Novo expects the FDA decision on the 2.4 mg / 2.4 mg dose in Q4 2026. The lower doses in REDEFINE 9 are not part of that filing. Until approval, CagriSema is only available inside clinical trials, and there is no approved compounded version. Anything sold online as “CagriSema” today is not an approved product. For where unapproved peptides stand legally, see our legal status tracker.
What it means for you
This is good news: one of the next weekly options looks strong even at lower doses, which could mean more flexible treatment if it is approved. It is still investigational, the trial was small, and the side effects are real. If you are weighing a GLP-1, talk to a licensed provider about the approved options available today and whether a future approval might fit. Our GLP-1 price tracker compares what the approved options cost, and our CagriSema in women post covers the full-dose data.
Sources
- Novo Nordisk via PR Newswire: CagriSema demonstrated ~21% average weight loss with lower doses in REDEFINE 9 (Nov 14, 2026)
- Healio: Lower-dose CagriSema reduces body weight vs. placebo (Nov 17, 2026)
- Novo Nordisk via PR Newswire: CagriSema associated with 25% mean weight loss among early responders, post hoc REDEFINE 1 (Nov 15, 2026)
Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.